Takeaways from Theranos for Worshippers of Mammon

Hitoshi Kokumai
2 min readJan 9, 2022

--

Out topic of today is “Theranos founder Elizabeth Holmes convicted in fraud trial” https://www.nprillinois.org/2022-01-04/theranos-founder-elizabeth-holmes-convicted-in-fraud-trial

We wouldn’t be surprise if some biometrics guys, who made quick money from the sales of security-lowering biometrics solutions or from such misleading promises by incorrectly touting them as security-increasing tools and thus spreading a false sense of security among the public, were having sleepless nights following the close of the colourful Theranos fraud drama.

As we have repeatedly stated, there is nothing wrong in selling biometrics solutions to be used with a default password as ‘Convenience-Enhancing Tool’ by explicitly declaring as such. However, we deem it very unethical to tout them as ‘Security-Enhancing Tool’ by misguiding the public to wrongly believe as such.

Legal people might possibly come to deem it criminal rather than simply unethical if they get convinced that those biometrics guys did it knowingly and deliberately. I wouldn’t be shocked at it.

An interesting aspect of biometrics as a security issue is that it would not help them if they claim that they unknowingly did it. Admitting that they were purely ignorant of the security effects of their products from which they raked in huge profits would certainly make it no better.

Security professionals and tech media who powerfully poured fuel on the firestorm of falsehood would no doubt find it hard to escape.

I expect 2022 to be the year of a big change in this sphere, enabling us to say goodbye to this menace to society.

Ref: “Negatively Effective Authenticator”

……………………………………………….

Corporate Website — https://www.mnemonicidentitysolutions.com/

--

--

Hitoshi Kokumai
Hitoshi Kokumai

Written by Hitoshi Kokumai

Advocate of ‘Identity Assurance by Our Own Volition and Memory’, Inventor of Expanded Password System and Founder of Mnemonic Identity Solutions Limited in UK.

No responses yet